The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) published the phase 2 results from its ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data for the novel, potential ...

Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Summit Therapeutics (SMMT – Research Report), boosting the price ...

Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ — At the 2024 European ...